Dual NK1/NK3 receptor antagonists
US7939533B2 · kind B2 · utility
3Cited by
1References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 29, 2009 |
| Grant date | May 10, 2011 |
| Priority date | — |
| Expiry date | Jul 3, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D513/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method for the treatment of schizophrenia which comprises administering a compound of formula
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.